The labeling updates address the risk of early-onset toxicity, including life-threatening adverse events in patients with DPD ...

Notice highlights risks of DPD deficiency with capecitabine, fluorouracil ...

The FDA has updated the safety labeling for the chemotherapeutic agents capecitabine (Xeloda) and fluorouracil (5-FU) to ...

Please provide your email address to receive an email when new articles are posted on . Overall survival of patients with metastatic colorectal cancer who completed 16 weeks of first-line chemotherapy ...

Systemic adjuvant or neoadjuvant chemotherapy, biologic, and hormone therapies have improved outcomes of patients with early-stage breast cancer. However, a substantial number of patients with ...

The FDA has approved the first generic formulation of capecitabine (Xeloda), an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer (mCRC) and ...

The FDA has approved neratinib (Puma Biotechnology), a kinase inhibitor, in combination with capecitabine, for the treatment of adult patients with advanced or metastatic human epidermal growth factor ...

A total of 144 patients were enrolled between April 2013 and March 2016 to temozolomide (n = 72) or capecitabine and temozolomide (n = 72); the primary analysis population included 133 eligible ...

Please provide your email address to receive an email when new articles are posted on . Capecitabine maintenance therapy significantly prolonged PFS among patients with newly diagnosed metastatic ...

Capecitabine is a chemotherapy drug used for breast and colorectal cancer. It can extend survival rate by nearly 10%. However, recent studies revealed that almost 50% of patients develop ...

Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established alternative to bolus fluorouracil plus ...